Luis Ramírez Martínez

Dr. Luis Ramírez Martínez


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
RPRonja Piesche
Ronja Piesche
Christophe CazabanChristophe Cazaban
Christophe Cazaban
LSLeticia Frizzo da Silva
Leticia Frizzo da Silva
LMLuis Ramírez Martínez
Luis Ramírez Martínez
HHHeike Hufen
Heike Hufen
CGChristian Grund
Christian Grund
Background/Objectives: The risk of the introduction of highly pathogenic avian influenza virus (HPAIV) in geese breeding and fattening flocks is heightened due to the necessity of free-range access to grazing grounds. This study aimed to evaluate the safety, immunogenicity, and protective efficacy of five commercial vaccines against HPAIV subtype H5N1 (clade 2.3.4.4b) in subadult fattening geese. Methods: A prime-boost vaccination trial was conducted using five commercial vaccines, including H5 expressing vaccines of novel technology (subunit, vector, RNA) and whole inactivated virus (WIV) vaccines. Based on serological results, one RNA and one WIV vaccine were selected for a homologous challenge experiment. Results: Two vaccines of novel technology (vector, RNA) required a booster dose to raise specific antibodies titers above a threshold of four log2 using a hemagglutination inhibition (HI) assay, whereas a subunit vaccine and two WIV vaccines induced seroconversion after primary vaccination. In the challenge experiment, all unvaccinated control geese succumbed to infection by day four. In contrast, all vaccinated geese that had seroconverted exhibited full clinical protection. Although sterile immunity was not achieved, viral excretion was significantly reduced in the vaccinated groups compared to controls. Conclusions: Vaccination substantially mitigated the impact of HPAIV H5N1, clade 2.3.4.4b infection in geese, greatly improving animal welfare by preventing severe disease. Additionally, there was a significant reduction in viral burden. Further studies are necessary to verify the potential of these vaccines to reduce susceptibility to infection and virus excretion in order to achieve suppression of the between-flock reproduction number to < 1 in geese flocks at high risk of infection.

22 March 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
MPMILTON NIETO PONCE
MILTON NIETO PONCE
Edgar Reyna-RosasEdgar Reyna-Rosas
Edgar Reyna-Rosas
RRRosa Andrea Andrea Palencia Reyes
Rosa Andrea Andrea Palencia Reyes
CBCarlos Blancas-Ruíz
Carlos Blancas-Ruíz
GAGuadalupe Aguilar-Rafael
Guadalupe Aguilar-Rafael
HZHORACIO ZAMUDIO-MEZA
HORACIO ZAMUDIO-MEZA
Background: An NDV-based vector has been used as a veterinary vaccine and, recently, as a human COVID-19 vaccine. However, data for the potential immune response against the vector in humans are scarce; therefore, it is important to evaluate the levels of antibodies produced. The HI assay is the gold standard for assessing the humoral response against NDV in poultry serum. Objective: Here, the objective was to validate the HI assay against the NDV-vectored vaccine to analyze antibodies in human serum. Methods: First, we standardized the conditions in human sera before validation. Results: The results for analytical performance in terms of selectivity, sensitivity, specificity, and positive and negative predictive values, as well as positive and negative diagnostic reliability, indicate that the assay is highly selective, allowing clear discrimination between positive and negative samples. Regarding repeatability and intermediate precision, we demonstrated that the assay has the precision to obtain consistent results, guaranteeing their reliability and truthfulness. Finally, the results regarding accuracy, linearity, and robustness indicate that the assay is accurate across the evaluated concentration intervals, with a linear correlation between low and high levels, and demonstrate that it is robust and consistent when serum–antigen interaction times are changed. Conclusions: We conclude that the suitability of the analytical method for its intended use is confirmed, guaranteeing the reliability of the results obtained under the established operating conditions.

11 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MPMILTON NIETO PONCE
MILTON NIETO PONCE
Edgar Reyna-RosasEdgar Reyna-Rosas
Edgar Reyna-Rosas
RRRosa Andrea Andrea Palencia Reyes
Rosa Andrea Andrea Palencia Reyes
CBCarlos Blancas-Ruíz
Carlos Blancas-Ruíz
GAGuadalupe Aguilar-Rafael
Guadalupe Aguilar-Rafael
HZHORACIO ZAMUDIO-MEZA
HORACIO ZAMUDIO-MEZA
NDV-based vector has been used as a veterinary vaccine and, recently also for human COVID-19 vaccine; however, data about the potential immune response against vector in humans is scarce, therefore, it is important evaluate levels of antibodies produced. The HI assay is the gold standard for assessing the humoral response against NDV in poultry serum. Here the objective of was validate the HI assay against the NDV-vectored vaccine to analyze antibodies in human serum. First, we standardized conditions in human sera before validation. The results from analytical performance: selectivity, sensitivity, specificity, positive and negative predictive value, as well as positive and negative diagnostic reliability, indicate that the assay is highly selective, as it allows clear discrimination between positive and negative samples. Regarding repeatability and inter-mediate precision, we demonstrated that the assay has precision to obtain consistent results and guarantees their reliability and truthfulness. Finally, the results of accuracy, linearity and robustness, indicate that the assay is accurate at the concentration intervals evaluated with a linear correlation between the low and high level and demonstrated that it is robust and consistent when the serum-antigen interaction times changed. We conclude that the suitability of the analytical method for its intended use is confirmed and guarantees the reliability of the results obtained under the established operating conditions.